肝细胞应激与金属硫蛋白在原发性硬化性胆管炎纤维化微环境中的作用研究进展

肝脏 ›› 2026, Vol. 31 ›› Issue (7): 935-939.

肝细胞应激与金属硫蛋白在原发性硬化性胆管炎纤维化微环境中的作用研究进展

王建香, 陆伦根

200080 上海上海交通大学医学院附属第一人民医院消化内科

收稿日期:2026-06-10 出版日期:2026-07-31 发布日期:2026-08-21

Received:2026-06-10 Online:2026-07-31 Published:2026-08-21

摘要/Abstract

摘要： 原发性硬化性胆管炎(PSC)是一种以胆管慢性炎症、进行性狭窄及胆汁淤积性肝纤维化为主要特征的免疫介导的疾病,常合并炎症性肠病,目前仍缺乏能够有效延缓疾病进展的治疗药物。近年来,单细胞RNA测序、单核RNA测序和空间转录组学等多组学技术推动了PSC病理机制的研究。近期研究发现,PSC纤维化病灶边缘存在金属硫蛋白(MT)高表达的应激性肝细胞,并伴随免疫细胞富集,提示肝细胞不仅可能是胆汁淤积损伤的靶细胞,还可能参与纤维化微环境的塑造。本文围绕PSC纤维化微环境中肝细胞应激、MT表达及免疫细胞浸润的研究进展进行综述,以期为PSC的疾病分层、机制研究及潜在干预策略提供参考。

关键词: 原发性硬化性胆管炎, 纤维化微环境, 肝细胞应激, 金属硫蛋白

王建香, 陆伦根. 肝细胞应激与金属硫蛋白在原发性硬化性胆管炎纤维化微环境中的作用研究进展[J]. 肝脏, 2026, 31(7): 935-939.

/ 推荐

参考文献

[1] Bowlus C L, Arrive L, Bergquist A, et al. AASLD Practice Guidance on primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2023, 77(2):659-702.
[2] Hov J R, Karlsen T H. The microbiota and the gut-liver axis in primary sclerosing cholangitis[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(3):135-154.
[3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis[J]. J Hepatol, 2022, 77(3):761-806.
[4] Chung B K, Jordens M S, Ogaard J, et al. Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis[J]. Hepatology, 2026, 83(5):1066-1081.
[5] Andrews T S, Nakib D, Perciani C T, et al. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver[J]. J Hepatol, 2024, 80(5):730-743.
[6] Chung B K, Ogaard J, Reims H M, et al. Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis[J]. Hepatol Commun, 2022, 6(9):2538-2550.
[7] Gribben C, Galanakis V, Calderwood A, et al. Acquisition of epithelial plasticity in human chronic liver disease[J]. Nature, 2024, 630(8015):166-173.
[8] Nakib D, MacParland S. Decoding the PSC fibrotic niche: hepatocyte stress and metallothioneins[J]. Hepatology, 2026, 83(5):1029-1032.
[9] Coyle P, Philcox J C, Carey L C, et al. Metallothionein: the multipurpose protein[J]. Cell Mol Life Sci, 2002, 59(4):627-647.
[10] Yang R, Roshani D, Gao B, et al. Metallothionein: a comprehensive review of its classification, structure, biological functions, and applications[J]. Antioxidants (Basel), 2024, 13(7):825.
[11] Alscher D M, Redmann D, Wehner F, et al. Metallothionein in liver-biopsies from patients with different diseases[J]. Exp Toxicol Pathol, 2002, 54(3):245-253.
[12] Mulder T P, Janssens A R, Verspaget H W, et al. Plasma metallothionein concentration in patients with liver disorders: special emphasis on the relation with primary biliary cirrhosis[J]. Hepatology, 1991, 14(6):1008-1012.
[13] Foligne B, George F, Standaert A, et al. High-dose dietary supplementation with zinc prevents gut inflammation: Investigation of the role of metallothioneins and beyond by transcriptomic and metagenomic studies[J]. FASEB J, 2020, 34(9):12615-12633.
[14] Guicciardi M E, Trussoni C E, Krishnan A, et al. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice[J]. J Hepatol, 2018, 69(3):676-686.
[15] Liu H, Yin G, Franco Leonardi B, et al. Reactive cholangiocyte-derived ORM2 drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming[J]. Gut, 2025, 74(10):1694-1710.
[16] Poch T, Krause J, Casar C, et al. Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4(+) T cells in primary sclerosing cholangitis[J]. J Hepatol, 2021, 75(2):414-423.
[17] Zimmer C L, von Seth E, Buggert M, et al. A biliary immune landscape map of primary sclerosing cholangitis reveals a dominant network of neutrophils and tissue-resident T cells[J]. Sci Transl Med, 2021, 13(599):eabb3107.
[18] Chung B K, Henriksen E K K, Jorgensen K K, et al. Gut and liver B cells of common clonal origin in primary sclerosing cholangitis-Inflammatory bowel disease[J]. Hepatol Commun, 2018, 2(8):956-967.
[19] Xu B, Broome U, Ericzon B G, et al. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6[J]. Gut, 2002, 51(1):120-127.
[20] ElAbd H, Pesesky M, Innocenti G, et al. T and B cell responses against Epstein-Barr virus in primary sclerosing cholangitis[J]. Nat Med, 2025, 31(7):2306-2316.
[21] Chu H, Li Y, Yang H, et al. Characterisation and clinical relevance of tertiary lymphoid structures in primary biliary cholangitis[J]. Liver Int, 2025, 45(4):e16157.